

A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380-an Oral Inhibitor of ErbB2

Array BioPharma

1.

✉ **Corresponding author:** Array BioPharma, array.biop@cureus.com

Categories: Oncology

Keywords:

How to cite this poster

Biopharma A (2012) A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380-an Oral Inhibitor of ErbB2. Cureus 4(9): e152.

Abstract

ARRY-380, dosed BID as powder-in-capsule (PiC) formulation, displayed an acceptable PK profile in cancer patients. At doses \geq 200 mg BID, 8/10 HER2+ patients had tumor regressions and, of these 8 patients, 4 received therapy for \geq 16 weeks.

Open Access

Published 09/24/2012

Copyright

© Copyright 2012

BioPharma. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Distributed under

Creative Commons CC-BY 3.0

